<?xml version="1.0" encoding="UTF-8"?>
<p id="para0033">Likewise, small scale preliminary studies with favipiravir, which targets RNA-dependent RNA polymerase, suggest partial beneficial effects [
 <xref rid="bib0060" ref-type="bibr">60</xref>,
 <xref rid="bib0061" ref-type="bibr">61</xref>]. Several randomized clinical trials (Phase 2 and 3) are testing efficacy of favipiravir in hospitalized patients with COVID-19. EIDD-2801 is a recently developed orally bioavailable ribonucleoside analogue, which inhibits SARS-CoV-2 replication 
 <italic>in vitro</italic> in human airway epithelial cells and improved pulmonary pathology in a mouse model 
 <xref rid="bib0062" ref-type="bibr">[62]</xref>. Safety, tolerability, and pharmacokinetic of EIDD-2801 has been tested in healthy individuals through a double-blind randomized placebo-controlled study (Phase 1). Phase 2 clinical trials are underway, however, the results are not yet available.
</p>
